Stock Comparison

ABBV vs ABCL

AbbVie Inc vs Abcellera Biologics Inc

The Verdict

ABCL takes this one.

ABBV

AbbVie Inc

0.1

out of 10

Distressed

Winner

ABCL

Abcellera Biologics Inc

7.2

out of 10

Solid Pick

Head-to-Head

$381.1B

Market Cap

$1.2B

104.8

P/E Ratio

-8.0

5.8%

Profit Margin

-194.9%

95.6%

Return on Equity

-14.8%

20.2

Debt-to-Equity

0.1

Moderate

Overall Risk

Aggressive

0.1

DVR Score

7.2

The Deep Dive

ABBV0.1/10

AbbVie (ABBV) remains a well-established mega-cap pharmaceutical company, demonstrating stable, incremental growth driven by its robust immunology portfolio, notably Skyrizi and Rinvoq. Q1 2026 results showed modest revenue and adjusted EPS growth, with slightly raised full-year guidance. While financially healthy and a strong dividend payer, its immense market capitalization ($381.10B) and the ma...

Full ABBV Analysis

ABCL7.2/10

AbCellera continues to hold significant 10x potential, driven by its cutting-edge AI-powered antibody discovery platform and a strategic pivot towards internal drug development. The substantial Q4 2025 revenue beat and the impending Phase 1/Phase 2 data for ABCL635 are strong positive catalysts, de-risking its pipeline and demonstrating execution. While the company still grapples with negative pro...

Full ABCL Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified advisor before investing.